Sufentanil NanoTab (sufentanil) / Talphera - LARVOL DELTA

Advancement in Nanotablet Research: An Overview. (PubMed, Recent Adv Drug Deliv Formul) - "Specifically, sublingual sufentanil nanotablets, such as Zalviso®, have demonstrated efficacy in managing moderate to severe pain in healthcare settings when used in conjunction with a PCA device. However, recent regulatory updates indicate changes in the marketing authorization status of Zalviso®. In conclusion, this novel approach for synthesizing nanotablets presents a promising avenue for diverse applications, and based on the results, it is worth considering for future work."

Journal • Oncology • Pain

An up-to-date overview of sublingual sufentanil for the treatment of moderate to severe pain. (PubMed, Expert Opin Pharmacother) - "Sublingual sufentanil nanotablets have been developed; 15 mcg tablet for a patient-controlled analgesia device and 30-mcg tablet for a single-dose device administered by a healthcare professional...The safety profile of sublingual sufentanil 30 mcg is typical to opioids nausea, vomiting, and sedation being the most common ones. Sublingual sufentanil 30-mcg nanotablet has the potential for efficient moderate to severe pain management in supervised healthcare facilities."

Journal • Anesthesia • Orthopedics • Pain